{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-026100","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.226579+00:00","generated_at":"2026-05-26T04:57:00.505068+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Candel: CAN-2409 final phase 2 data shows median OS 31.4 mo vs 12.5 mo in pancreatic cancer","bullets":["Estimated median overall survival 31.4 months in CAN-2409 arm vs 12.5 months in control (borderline resectable PDAC).","Three of seven CAN-2409-treated patients still alive at data cut-off (66.0, 63.6, 35.8 months post-enrollment).","Median survival post-progression was 21.2 months with CAN-2409 vs 7.2 months in control arm.","No dose-limiting toxicities or pancreatitis; favorable safety profile.","Company plans to advance CAN-2409 into a larger late-stage randomized trial in PDAC."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-026100","json":"https://secwatch.observer/filing/0000950170-25-026100.json","markdown":"https://secwatch.observer/filing/0000950170-25-026100.md","text":"https://secwatch.observer/filing/0000950170-25-026100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025026100/0000950170-25-026100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025026100/cadl-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:57:00.505068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}